OKYO: Utang jangka cendhak perusahaan OKYO Pharma Ltd

OKYO Pharma Limited (OKYO) is collaborating with ophthalmology clinics to develop anti-inflammatory drops to combat dry eye syndrome. This chart of current debt obligations helps assess the credit load, where the 0.00 mark indicates the current status. The stability of active ingredient supplies is ensured through the diversification of contract manufacturing. While the company currently lacks pricing power, successful trials will create opportunities for premium pricing.

Optimizing the liability structure directly impacts the fundamental stability of OKYO Pharma Limited (OKYO), determining its margin of safety prior to entering the commercial market. The dynamics of current short-term liabilities reflect the risk of cash flow gaps and the cost of borrowing, which is critical for sustaining prolonged clinical trials of dry eye syndrome drugs until FDA approval is obtained.